A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
NCT03062943
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Lymphangioleiomyomatosis
Interventions
DRUG:
Nintedanib
Sponsor
IRCCS Multimedica